Published in Eur J Clin Microbiol Infect Dis on January 01, 1997
Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis. BMC Infect Dis (2014) 1.25
Antifungal activity of redox-active benzaldehydes that target cellular antioxidation. Ann Clin Microbiol Antimicrob (2011) 0.90
Enhancement of antimycotic activity of amphotericin B by targeting the oxidative stress response of Candida and cryptococcus with natural dihydroxybenzaldehydes. Front Microbiol (2012) 0.87
A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis. Nat Protoc (2010) 0.87
Ultrastructural analysis of Candida albicans when exposed to silver nanoparticles. PLoS One (2014) 0.83
Targeting the oxidative stress response system of fungi with redox-potent chemosensitizing agents. Front Microbiol (2012) 0.80
Antidermatophytic Activity of Mikania micrantha Kunth: An Invasive Weed. Pharmacognosy Res (2015) 0.79
Enhancement of commercial antifungal agents by Kojic Acid. Int J Mol Sci (2012) 0.77
Investigation of aryl isonitrile compounds with potent, broad-spectrum antifungal activity. Bioorg Med Chem (2017) 0.75
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother (1995) 5.74
Antifungal susceptibility tests. Antimicrob Agents Chemother (1987) 4.76
Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.25
Oral azole drugs as systemic antifungal therapy. N Engl J Med (1994) 3.96
Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) (1990) 3.95
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis (1994) 3.62
Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis (1996) 3.52
Coccidioidomycosis. N Engl J Med (1995) 3.01
Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother (1994) 2.99
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1995) 2.62
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother (1992) 2.39
In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother (1995) 2.37
Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med (1995) 2.33
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis (1995) 2.11
Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis (1986) 2.08
A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med (1991) 2.06
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis (1994) 1.99
A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med (1995) 1.94
Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med (1996) 1.91
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother (1993) 1.83
Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1993) 1.82
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis (1991) 1.70
Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis (1995) 1.64
Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med (1994) 1.58
Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient. Clin Infect Dis (1993) 1.49
Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother (1995) 1.42
Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother (1994) 1.41
Amphotericin B induces tumor necrosis factor production by murine macrophages. J Infect Dis (1989) 1.40
Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother (1995) 1.40
In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother (1995) 1.39
Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1992) 1.29
Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies. Rev Infect Dis (1990) 1.29
Treatment of murine histoplasmosis with UK 49,858 (fluconazole). Am Rev Respir Dis (1986) 1.23
Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections. Ann Intern Med (1986) 1.18
Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int J STD AIDS (1996) 1.16
Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med (1993) 1.11
High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. J Infect Dis (1994) 1.08
Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob Agents Chemother (1991) 1.05
Inactivation of amphotericin B by reducing agents: influences on growth inhibition of Candida albicans and lysis of erythrocytes. Sabouraudia (1972) 1.00
Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis (1995) 0.99
Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother (1992) 0.98
Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med (1994) 0.97
Interaction of chemotherapy and immune defenses in experimental murine cryptococcosis. Antimicrob Agents Chemother (1978) 0.96
In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole. J Antimicrob Chemother (1990) 0.95
Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood (1991) 0.94
Discrepancies between MIC and MLC values of amphotericin B against isolates of Aspergillus species. Mycopathologia (1994) 0.94
Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis (1993) 0.91
Annulment of amphotericin B inhibition of Coccidioides immitis endospores. Effects on growth, respiration and morphogenesis. Sabouraudia (1969) 0.91
Amphotericin B in the treatment of coccidioidomycosis. Drugs (1983) 0.81
Protective effect of human granulocyte colony stimulating factor (hG-CSF) on Candida infections in normal and immunosuppressed mice. Mycoses (1992) 0.79
Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother (1996) 3.40
Extended-spectrum beta-lactamases: epidemiology, detection, and treatment. Pharmacotherapy (2001) 1.46
Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol (2000) 1.28
Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. Diagn Microbiol Infect Dis (2000) 1.12
Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother (1997) 1.12
High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother (1991) 1.12
Effect of removal of duplicate isolates on cumulative susceptibility reports. Diagn Microbiol Infect Dis (2001) 1.06
Determination of moxalactam in human body fluids by liquid chromatographic and microbiological methods. Antimicrob Agents Chemother (1981) 1.02
Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther (2000) 1.00
Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit. Bone Marrow Transplant (2007) 0.88
Treatment of aspergillosis with itraconazole. Ann Pharmacother (1993) 0.87
Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother (1999) 0.84
Continuous infusion beta-lactams for intensive care unit pulmonary infections. Clin Microbiol Infect (2005) 0.79
Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Clin Ther (1999) 0.79
Treatment of thrush with itraconazole solution: evidence for topical effect. Clin Infect Dis (1998) 0.78
Latamoxef (moxalactam) kinetics in volunteers studied by a specific HPLC assay technique. J Antimicrob Chemother (1983) 0.78
Itraconazole-didanosine excipient interaction. JAMA (1993) 0.77
The use of vasopressin in the treatment of upper gastrointestinal haemorrhage. Drugs (1990) 0.77
Biological effects of cocaine derivatives I: Improved synthesis and pharmacological evaluation of norcocaine. J Pharm Sci (1977) 0.77
Who should receive antiendotoxin monoclonal antibody therapy? Clin Pharm (1992) 0.75
A critical pathway for treatment of community-acquired pneumonia. JAMA (2000) 0.75
Cytokine mediators of malnutrition: clinical implications. Nutr Clin Pract (1993) 0.75
Vancomycin-resistant enterococci osteomyelitis in the foot. A case report. J Am Podiatr Med Assoc (1997) 0.75
Added qualifications for pharmacy specialists: another perspective. Ann Pharmacother (1997) 0.75
Rapid replacement of serum albumin in patients receiving total parenteral nutrition. Surg Gynecol Obstet (1986) 0.75
Drug degradation during HPLC analysis of aztreonam: effect on pharmacokinetic parameter estimation. Ann Pharmacother (1994) 0.75
Phenytoin-induced pseudolymphoma with mycosis fungoides manifestations. Clin Pharm (1988) 0.75
Physician perceptions of a clinical pharmacy program. Am J Hosp Pharm (1982) 0.75
Compatibility of 5-fluorouracil and total parenteral nutrition solutions. JPEN J Parenter Enteral Nutr (1982) 0.75
Cancer cachexia: the metabolic alterations. Nutr Clin Pract (1988) 0.75
Experience with 3-liter bags for total parenteral nutrition delivery. JPEN J Parenter Enteral Nutr (1984) 0.75
Desipramine-induced agranulocytosis. A case report. Drug Intell Clin Pharm (1982) 0.75
Amphotericin B enzyme-linked immunoassay for clinical use: comparison with bioassay and HPLC. Ann Pharmacother (1997) 0.75
Trends in antifungal research. EXS (2000) 0.75
Profile of stated drug allergies in hospitalized patients. Am J Hosp Pharm (1981) 0.75
Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma. Am J Hosp Pharm (1992) 0.75
Aminoglycosides, imipenem, and aztreonam. Clin Podiatr Med Surg (1992) 0.75
A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence. J Urol (1989) 0.75